Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELU NASDAQ:SNTI NASDAQ:TNFA NASDAQ:TVRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELUCelularity$1.05+2.7%$1.08$0.71▼$4.35$30.37M0.48145,369 shs102,472 shsSNTISenti Biosciences$1.00+2.0%$0.95$0.77▼$3.88$30.99M2.08197,311 shs104,215 shsTNFATNF Pharmaceuticals$3.85-6.1%$3.85$0.04▼$8.94$7.11M2.0432.22 million shs343,897 shsTVRDTvardi Therapeutics$3.03+2.7%$3.37$2.75▼$43.65$28.61M0.3357,501 shs17,266 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELUCelularity-3.77%+11.46%+6.58%-15.00%-56.03%SNTISenti Biosciences-0.86%-3.44%-4.38%+3.97%-69.04%TNFATNF Pharmaceuticals-2.38%+4.06%+9.92%+10.81%-75.57%TVRDTvardi Therapeutics-6.94%-10.61%-6.05%-26.62%-88.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELUCelularity$1.05+2.7%$1.08$0.71▼$4.35$30.37M0.48145,369 shs102,472 shsSNTISenti Biosciences$1.00+2.0%$0.95$0.77▼$3.88$30.99M2.08197,311 shs104,215 shsTNFATNF Pharmaceuticals$3.85-6.1%$3.85$0.04▼$8.94$7.11M2.0432.22 million shs343,897 shsTVRDTvardi Therapeutics$3.03+2.7%$3.37$2.75▼$43.65$28.61M0.3357,501 shs17,266 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELUCelularity-3.77%+11.46%+6.58%-15.00%-56.03%SNTISenti Biosciences-0.86%-3.44%-4.38%+3.97%-69.04%TNFATNF Pharmaceuticals-2.38%+4.06%+9.92%+10.81%-75.57%TVRDTvardi Therapeutics-6.94%-10.61%-6.05%-26.62%-88.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELUCelularity 2.00Hold$6.00488.24% UpsideSNTISenti Biosciences 2.80Moderate Buy$8.75797.16% UpsideTNFATNF Pharmaceuticals 1.00SellN/AN/ATVRDTvardi Therapeutics 2.43Hold$53.601,716.95% UpsideCurrent Analyst Ratings BreakdownLatest TNFA, CELU, SNTI, and TVRD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026SNTISenti Biosciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $12.004/21/2026SNTISenti Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026TVRDTvardi Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/1/2026TVRDTvardi Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.003/30/2026SNTISenti Biosciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELUCelularity$26.55M1.11N/AN/A($1.32) per share-0.77SNTISenti Biosciences$20K1,519.03N/AN/A$0.18 per share5.42TNFATNF PharmaceuticalsN/AN/AN/AN/A$286.76 per shareN/ATVRDTvardi Therapeutics$7.14M3.88N/AN/A$2.23 per share1.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELUCelularity-$91.72M-$3.33N/AN/AN/A-345.45%N/A-77.94%8/12/2026 (Estimated)SNTISenti Biosciences-$61.44M-$1.92N/AN/AN/AN/A-532.05%-103.35%8/6/2026 (Estimated)TNFATNF Pharmaceuticals-$23.36M-$231.00N/AN/AN/AN/A-69.21%-33.98%N/ATVRDTvardi Therapeutics-$18.21M-$3.10N/AN/AN/AN/A-64.17%-43.90%N/ALatest TNFA, CELU, SNTI, and TVRD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026SNTISenti Biosciences-$0.36-$0.14+$0.22-$0.14$0.02 million$0.02 million5/8/2026Q1 2026TVRDTvardi Therapeutics-$0.65-$0.73-$0.08-$0.73N/AN/A4/30/2026Q4 2025CELUCelularityN/A-$0.85N/A-$0.85N/A$4.10 million3/31/2026Q4 2025TVRDTvardi Therapeutics-$0.55-$0.78-$0.23-$0.78N/AN/A3/27/2026Q4 2025SNTISenti Biosciences-$0.43-$0.53-$0.10-$0.53$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCELUCelularityN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELUCelularityN/A0.150.15SNTISenti BiosciencesN/A1.041.04TNFATNF PharmaceuticalsN/A0.930.93TVRDTvardi TherapeuticsN/A2.252.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELUCelularity19.02%SNTISenti Biosciences25.70%TNFATNF Pharmaceuticals9.64%TVRDTvardi Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipCELUCelularity17.30%SNTISenti Biosciences3.12%TNFATNF Pharmaceuticals0.45%TVRDTvardi Therapeutics7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELUCelularity22028.95 million23.94 millionOptionableSNTISenti Biosciences431.15 million30.17 millionNot OptionableTNFATNF Pharmaceuticals61.85 million1.84 millionN/ATVRDTvardi Therapeutics809.38 million8.69 millionN/ATNFA, CELU, SNTI, and TVRD HeadlinesRecent News About These CompaniesTvardi Therapeutics to Participate in Upcoming Investor EventsMay 21, 2026 | globenewswire.comOppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)May 13, 2026 | theglobeandmail.comTvardi Therapeutics (TVRD) Receives a Buy from BTIGMay 11, 2026 | theglobeandmail.comTvardi: Q1 Earnings SnapshotMay 8, 2026 | wtop.comWTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business UpdateMay 8, 2026 | globenewswire.comBarclays downgrades Tvardi Therapeutics (TVRD)April 21, 2026 | msn.comTvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50April 9, 2026 | msn.comBarclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)April 8, 2026 | theglobeandmail.comTvardi Therapeutics to Participate in the Raymond James Biotech Innovation SymposiumApril 2, 2026 | globenewswire.comTvardi: Q4 Earnings SnapshotApril 1, 2026 | stamfordadvocate.comSTvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business UpdateMarch 31, 2026 | globenewswire.comTvardi Therapeutics to Participate in Upcoming Investor ConferencesFebruary 12, 2026 | markets.businessinsider.comWe're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn RateFebruary 7, 2026 | finance.yahoo.comTvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2026 | globenewswire.comTvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsJanuary 8, 2026 | markets.businessinsider.comINVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 27, 2025 | newsfilecorp.comNTVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 24, 2025 | globenewswire.comINVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 23, 2025 | prnewswire.comTVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 21, 2025 | businesswire.comSHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsDecember 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNFA, CELU, SNTI, and TVRD Company DescriptionsCelularity NASDAQ:CELU$1.05 +0.03 (+2.75%) As of 02:05 PM Eastern This is a fair market value price provided by Massive. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Senti Biosciences NASDAQ:SNTI$1.00 +0.02 (+2.02%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.TNF Pharmaceuticals NASDAQ:TNFA$3.85 -0.25 (-6.10%) As of 06/3/2026TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Tvardi Therapeutics NASDAQ:TVRD$3.03 +0.08 (+2.75%) As of 02:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker Ulta's Q1 Report Primes It for a Beauty of a Rebound Palo Alto Networks Accelerates Growth 31% on AI Demand How the Memory Shortage Is Crushing the Gaming Industry As AI Data Breaches Become More Common, This Cybersecurity ETF Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
